Searched for
QUALITY STANDARDS FOR BIOSIMILARS
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- Dr Reddy’s launches oral semaglutide in IndiaDr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Aurobindo Pharma arm CuraTeQ gets Health Canada nod for biosimilarAurobindo Pharma announced a significant development today. Its subsidiary, CuraTeQ Biologics, has received a compliance notice from Health...
- Compliance squeeze, global scrutiny redefine India’s $30 billion pharma export playbookAs global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.
- Zydus Lifesciences in focus after USFDA clears Ahmedabad plant, Aflibercept biosimilar launchZydus Lifesciences is in focus after receiving USFDA clearance with zero observations for its Ahmedabad facility and launching ANYRA, India...
- Budget 2026: Sitharaman proposes Rs 10,000-crore Biopharma Shakti scheme to boost biopharma manufacturingThe proposed fund aims to position India as a global biopharma manufacturing hub
- Aurobindo Pharma’s Dyrupeg faces Health Canada compliance noticeCuraTeQ Biologics, a part of Aurobindo Pharma, has secured a crucial approval from Health Canada for its biosimilar drug Dyrupeg. This medi...
- Biocon's Bengaluru drug manufacturing facility gets 'Voluntary Action Indicated' classificationBiocon Biologics' drug substance facility in Bengaluru has been classified as Voluntary Action Indicated (VAI) by the USFDA. This classific...
- Civil society organisations urge govt to scrap animal testing in biosimilar developmentCivil society organizations are urging the health ministry to eliminate animal studies in biosimilar development to lower production costs ...
- Comments sought on biosimilars guidelinesIndia's drug regulator has released draft guidelines for biosimilar drugs, inviting public comments within 30 days. These revised regulatio...
- Revised rules for biosimilar drugs enter the final stretchThe Indian government is refining biosimilar drug regulations, aligning with global standards to ensure stringent quality in research and m...
- Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plantBiocon Biologics received EMA approval to manufacture biosimilar Bevacizumab in Bengaluru, providing additional capacity to address patient...
- Tata Capital picks up 0.85% stake in Biocon Biologics for $30 millionPost the completion of this transaction, Biocon will hold a 95.25 per cent stake in Biocon Biologics.
- We are becoming more of a solutions company: Kieran MurphyThe CEO of $4-billion GE Healthcare Life Sciences, Kieran Murphy, discusses how drug makers are adopting modern ways of building "flexible ...
- Changes proposed in norms to speed up approvals for biosimilarsBiosimilars are copies of complex drugs based on living cells. They are different from chemical-based generic drugs, which are 'identical' ...
- India offers better opportunity for biosimilar drugs: Cadila Healthcare founder Pankaj PatelBiosimilars are follow-on versions of biologic drugs and far more complex and more difficult to copy than generic drugs because of the stru...
- How Dr Reddy’s is rebooting its biosimilars playDr Reddy’s was among the first to race off the blocks with four launches in India about as many years. But things have slowed since.
Load More
